Patent application number | Description | Published |
20110031122 | METHOD FOR DETECTING DISEASE MARKERS - Disease specific markers, in particular cancer markers, can be detected by electrophoretically separating proteins and protein complexes from a biological sample on a protein binding polymeric membrane in a low conductivity, water-miscible organic solvent buffer. Electrophoretic separation profiles representing different diseases can be produced, and used in the diagnosis or prognosis of these diseases. | 02-10-2011 |
20120183555 | SERUM MARKERS ASSOCIATED WITH EARLY AND OTHER STAGES OF BREAST CANCER - Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers. | 07-19-2012 |
20120219570 | G-PROTEIN COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1 AS A CANCER BIOMARKER - A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed. | 08-30-2012 |
20130183317 | G-PROTEIN COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1 AS A CANCER BIOMARKER - A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed. | 07-18-2013 |
Patent application number | Description | Published |
20090043016 | FLAME RETARDANT POLYTRIMETHYLENE TEREPHTHALATE COMPOSITION - Improved flame retardant polytrimethylene terephthalate compositions are provided by including a fluorinated sulfonate salt as a flame retardant additive. | 02-12-2009 |
20090043017 | FLAME RETARDANT POLYTRIMETHYLENE TEREPHTHALATE COMPOSITION - Improved flame retardant polytrimethylene terephthalate compositions are provided by including a perfluorinated sulfonate salt as a flame retardant additive. | 02-12-2009 |
20090043019 | FLAME RETARDANT POLYTRIMETHYLENE TEREPHTHALATE COMPOSITION - Improved flame retardant polytrimethylene terephthalate compositions are provided by including a brominated flame retardant additive. | 02-12-2009 |
20090043020 | FLAME RETARDANT POLYTRIMETHYLENE TEREPHTHALATE COMPOSITION - Improved flame retardant polytrimethylene terephthalate compositions are provided by including a melamine cyanurate flame retardant additive. | 02-12-2009 |
20090043021 | FLAME RETARDANT POLYTRIMETHYLENE TEREPHTHALATE COMPOSITION - Improved flame retardant polytrimethylene terephthalate compositions are provided by including a certain phosphorous compound as a flame retardant additive. | 02-12-2009 |
20110172329 | FLAME RETARDANT POLY(TRIMETHYLENE TEREPHTHALATE) COMPOSITION - Improved flame retardant polytrimethylene terephthalate compositions are provided by including a bis(diphenyl phosphate) flame retardant additive. | 07-14-2011 |
20110311759 | FLAME RETARDANT PERFORMANCE IN POLY (TRIMETHYLENE) TEREPHTHALATE - Poly(trimethylene terephthalate) compositions, and articles made therefrom, having improved flame retardancy are provided. The compositions can be used to make carpets that are suitable for installation where flame retardancy is desired. | 12-22-2011 |
20120282431 | MIXED POLYESTER YARNS AND ARTICLES MADE THEREFROM - The present invention is directed to polyester yarns made from two or more different polyesters. The invention is also directed to finished articles made from two or more different polyesters, and especially to carpets. | 11-08-2012 |
20130029086 | POLY-TRIMETHYLENE TEREPHTHALATE SOLID CORE FIBRILLATION-RESISTANT FILAMENT HAVING A SUBSTANTIALLY TRIANGULAR CROSS SECTION, A SPINNERET FOR PRODUCING THE FILAMENT, AND A CARPET MADE THEREFROM - In a first aspect the invention is a solid core fibrillation-resistant, synthetic polymeric filament having three substantially equal length convex sides. The sides through substantially rounded tips centered by a distance “a” from the axis of the filament. Each rounded tip has a radius substantially equal to a length “b”. Each tip lies on a circumscribed circle having a radius substantially equal to a length (a+b) and the midpoint of each side lies on an inscribed circle having a radius substantially equal to a length “c”. The filament has a denier-per-filament in the range 10<“dpf”<35; the distance “a” lies in the range 0.00025 inches (6 micrometers)<“a”<0.004 inches (102 micrometers); the distance “b” lies in the range from 0.00008 inches (2 micrometers)<“b”<0.001 inches (24 micrometers); the distance “c” lies in the range from 0.0003 inches (8 micrometers)<“c”<0.0025 inches (64 micrometers); and the modification ratio (“MR”) lies in the range from about 1.1<“MR”01-31-2013 | |
20130029152 | POLY-TRIMETHYLENE TEREPHTHALATE SOLID CORE FIBRILLATION-RESISTANT FILAMENT HAVING A SUBSTANTIALLY TRIANGULAR CROSS SECTION, A SPINNERET FOR PRODUCING THE FILAMENT, AND A CARPET MADE THEREFROM - In a first aspect the invention is a solid core fibrillation-resistant, synthetic polymeric filament having three substantially equal length convex sides. The sides through substantially rounded tips centered by a distance “a” from the axis of the filament. Each rounded tip has a radius substantially equal to a length “b”. Each tip lies on a circumscribed circle having a radius substantially equal to a length (a+b) and the midpoint of each side lies on an inscribed circle having a radius substantially equal to a length “c”. The filament has a denier-per-filament in the range 10<“dpf”<35; the distance “a” lies in the range 0.00025 inches (6 micrometers)<“a”<0.004 inches (102 micrometers); the distance “b” lies in the range from 0.00008 inches (2 micrometers)<“b”<0.001 inches (24 micrometers); the distance “c” lies in the range from 0.0003 inches (8 micrometers)<“c”<0.0025 inches (64 micrometers); and the modification ratio (“MR”) lies in the range from about 1.1<“MR”01-31-2013 | |
20130034658 | POLY-TRIMETHYLENE TEREPHTHALATE SOLID CORE FIBRILLATION-RESISTANT FILAMENT HAVING A SUBSTANTIALLY TRIANGULAR CROSS SECTION, A SPINNERET FOR PRODUCING THE FILAMENT, AND A CARPET MADE THEREFROM - In a first aspect the invention is a solid core fibrillation-resistant, synthetic polymeric filament having three substantially equal length convex sides. The sides through substantially rounded tips centered by a distance “a” from the axis of the filament. Each rounded tip has a radius substantially equal to a length “b”. Each tip lies on a circumscribed circle having a radius substantially equal to a length (a+b) and the midpoint of each side lies on an inscribed circle having a radius substantially equal to a length “c”. The filament has a denier-per-filament in the range 10<“dpf”<35; the distance “a” lies in the range 0.00025 inches (6 micrometers)<“a”<0.004 inches (102 micrometers); the distance “b” lies in the range from 0.00008 inches (2 micrometers)<“b”<0.001 inches (24 micrometers); the distance “c” lies in the range from 0.0003 inches (8 micrometers)<“c”<0.0025 inches (64 micrometers); and the modification ratio (“MR”) lies in the range from about 1.1<“MR”02-07-2013 | |
20160069018 | FLAME RETARDANT POLY(TRIMETHYLENE) TEREPHTHALATE COMPOSITIONS AND ARTICLES MADE THEREFROM - Poly(trimethylene terephthalate) compositions, and articles made therefrom, having improved flame retardancy are provided. The compositions can be used to make carpets that are suitable for installation where flame retardancy is desired. | 03-10-2016 |
Patent application number | Description | Published |
20110189771 | Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity and Reducted Toxicity - Imino sugars, such as deoxynojirimycin (DNJ), are glucose analogues that selectively inhibit cellular α-glucosidase I and II (enzymes that process N-linked glycans in glycoprotein) and exhibit broad spectrum antiviral activities against many enveloped viruses. Previously we have reported a novel DNJ derivative, OSL-95II, with antiviral activity and reduced cytotoxicity. In order to develop imino sugars with more potent antiviral activity as well as improved toxicity profile, OSL-95II was modified by diversifying the nitrogen linked alkylated side chain. The antiviral activities were initially tested in bovine viral diarrhea virus (BVDV) infected MDBK cells, yielding several imino sugar derivatives with novel structure and superior antiviral activity and toxicity profile. Furthermore, these new compounds were shown to be active against Dengue virus (DV) and West Nile virus (WNV) infection in BHK cells where potent anti-DV activity having submicromolar EC50 values and SI of greater than 900. These compounds represent a new generation of iminio sugars and their analogues, having application in the clinical treatment of infection of DV and other members of flaviviridae. | 08-04-2011 |
20150119366 | Novel Alkylated Imino Sugars Exhibiting Glucosidase Inhibition and Their Method of Use - Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity. | 04-30-2015 |
20150265672 | MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION - The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject. | 09-24-2015 |
20150335630 | Novel Alkylated Imino Sugars Exhibiting Glucosidase Inhibition and Their Method of Use - Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity. | 11-26-2015 |
Patent application number | Description | Published |
20110194418 | IDENTIFICATION OF A FAULT - An apparatus, method, and system are provided for determining a location of an error source. Equalization coefficients may be retrieved and an average period of time between localized peak amplitudes may be determined. The average period of time may be multiplied by a velocity of propagation associated with a communication channel to determine an approximate location of the error source. The equalization coefficients may correspond to the inverse of the frequency response associated with the communication channel and may be updated over time using replacement or combination (e.g., convolution) techniques. | 08-11-2011 |
20110194597 | MODULATION ANALYSIS AND DISTORTION IDENTIFICATION - An apparatus, method, computer readable medium, and system are provided to generate a symbol placement associated with a transmission scheme by transforming a retrieved set of equalization coefficients. Symbols included in the symbol placement may be analyzed and quantified in terms of their distance from a decision boundary. Symbols may be synthesized on an iterative basis in order to obtain visibility into the underlying performance of the transmission scheme over time. If equalization is unable to reduce a signal impairment below a threshold value within a predetermined amount of time, then a determination may be made that a non-linear distortion source is present in a network or communication system. Signals received from a plurality of user terminals may be compared with one another in order to determine a probable location or cause of the non-linear distortion. | 08-11-2011 |
20110197071 | Determining Response Signature Commonalities - An analyzer can obtain data regarding signal characteristics in each of multiple communication channels within an access network. The analyzer can use that data to create signatures corresponding to each of the multiple channels. Based on similarities between signatures, the analyzer may then identify clusters of signatures associated with devices that share channels or portions of channels. | 08-11-2011 |
20110243214 | INDUCING RESPONSE SIGNATURES IN A COMMUNICATION NETWORK - Methods and systems are provided in which a network induces different distortions in signals traversing different segments of the network. The distortions may be used to identify locations on the network of devices that transmit and receive the signals. The distortions may be reflected in equalization coefficients programmed into transmitting or receiving devices, which may be used to pre or post filter the signals to compensate for the distortions. | 10-06-2011 |
20140241409 | MODULATION ANALYSIS AND DISTORTION IDENTIFICATION - An apparatus, method, computer readable medium, and system are provided to generate a symbol placement associated with a transmission scheme by transforming a retrieved set of equalization coefficients. Symbols included in the symbol placement may be analyzed and quantified in terms of their distance from a decision boundary. Symbols may be synthesized on an iterative basis in order to obtain visibility into the underlying performance of the transmission scheme over time. If equalization is unable to reduce a signal impairment below a threshold value within a predetermined amount of time, then a determination may be made that a non-linear distortion source is present in a network or communication system. Signals received from a plurality of user terminals may be compared with one another in order to determine a probable location or cause of the non-linear distortion. | 08-28-2014 |
20150046982 | Determining Response Signature Commonalities - An analyzer can obtain data regarding signal characteristics in each of multiple communication channels within an access network. The analyzer can use that data to create signatures corresponding to each of the multiple channels. Based on similarities between signatures, the analyzer may then identify clusters of signatures associated with devices that share channels or portions of channels. | 02-12-2015 |
20150256430 | INDUCING RESPONSE SIGNATURES IN A COMMUNICATION NETWORK - Methods and systems are provided in which a network induces different distortions in signals traversing different segments of the network. The distortions may be used to identify locations on the network of devices that transmit and receive the signals. The distortions may be reflected in equalization coefficients programmed into transmitting or receiving devices, which may be used to pre or post filter the signals to compensate for the distortions. | 09-10-2015 |
Patent application number | Description | Published |
20120232076 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 09-13-2012 |
20120252828 | PYRIDOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 10-04-2012 |
20120264761 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators - The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 10-18-2012 |
20150218164 | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS - The present invention relates to Substituted Naphthyridinedione Derivatives and pharmaceutically acceptable salts thereof. The present invention also relates to compositions comprising at least one Substituted Naphthyridinedione Derivative, and methods of using the Substituted Naphthyridinedione Derivatives for treating or preventing HIV infection in a subject. | 08-06-2015 |
Patent application number | Description | Published |
20100222355 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 09-02-2010 |
20100324024 | Quinolizidinone M1 Receptor Positive Allosteric Modulators - The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 12-23-2010 |
20110046145 | Quinolizidinone M1 Receptor Positive Allosteric Modulators - The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 02-24-2011 |
20110112077 | Quinolizidinone m1 Receptor Positive Allosteric Modulators - The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 05-12-2011 |
20120157438 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 06-21-2012 |
20130184298 | DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 07-18-2013 |
20130338106 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY - Disclosed are compounds of Formula I: and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO | 12-19-2013 |
20140200197 | HIV PROTEASE INHIBITORS - The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. | 07-17-2014 |
20140364395 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators - The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) | 12-11-2014 |
Patent application number | Description | Published |
20080230369 | Propylene oxide recovery process - Product propylene oxide in a reaction mixture resulting from the reaction of propylene, oxygen and hydrogen or from the reaction of propylene and hydrogen peroxide is separated from propylene and/or propane by extractive distillation using methanol and/or water extractive distillation solvent. | 09-25-2008 |
20080300417 | Slurry reaction system - The present invention provides a slurry reaction system wherein liquid reaction mixture containing catalyst fines is separated from catalyst particles of a size suitable for use in the slurry reaction in a first separation step and in a subsequent separation step the catalyst fines are separated from liquid reaction mixture. | 12-04-2008 |
20090247773 | Propylene oxide process - A process for making propylene oxide from propylene is disclosed. Propylene, hydrogen, and oxygen are reacted in a slurry comprising a catalyst and a solvent to produce a gaseous product stream and a liquid product stream. The gaseous product stream is contacted with an absorbent to produce a gas effluent and a liquid effluent. The gas effluent is recycled to the reaction step. | 10-01-2009 |
20090306416 | Propylene oxide process - A process for making propylene oxide from propylene is disclosed. The process comprises reacting propylene, oxygen, and hydrogen in the presence of a catalyst, a solvent, and a buffer to produce a reaction mixture comprising propylene oxide. Separation of light components from the reaction mixture gives a heavy residue comprising the buffer. The buffer is precipitated from the heavy residue by a precipitating agent. | 12-10-2009 |
20100056814 | PROPYLENE OXIDE PROCESS - A process for making propylene oxide from propylene is disclosed. The process comprises reacting propylene, oxygen, and hydrogen in the presence of a catalyst and a solvent to produce a reaction mixture comprising propylene oxide. Separation of propylene, oxygen, hydrogen, and propylene oxide from the reaction mixture results in a residual mixture comprising methanol. A portion of the residual mixture is recycled to the reaction. A portion of the residual mixture is distilled to generate a distilled methanol stream, which is recycled to the reaction. | 03-04-2010 |
20120312680 | ALKYLENE OXIDE SEPARATION SYSTEMS, METHODS, AND APPARATUSES - The disclosure relates to a process for separating propylene oxide for a crude propylene oxide stream, for example an intermediate stream from a PO/TBA process. The crude propylene oxide stream can be passed through an extractive distillation column. The distillation column is operated at a pressure in a range of greater than 25 up to 50 psig, and/or at a temperature in a range of from 70 to 150 degrees Celsius using C | 12-13-2012 |
Patent application number | Description | Published |
20120019592 | Print head mounting and adjusting mechanism - An improved print head mounting and adjusting mechanism for inkjet printers. The mechanism include a bottom bracket and a base plate, the bottom bracket is installed on the base plate, the bottom bracket can be used for mounting print head, wherein said bottom bracket is supported by two stainless steel round shaft which is mounted on the base plate to provide accurate Y-axis movement and adjustment. Micrometer screw head is used as the adjustment mechanism for fine precision adjustment. The bottom bracket moves along a stainless steel round shaft to prevent deflection while adjusting. The print head and the adjustment mechanism are two separate parts, so exchanging or adjusting it will not damage the print heads. Remounting a print head requires a slight adjustment to reach the desired position reducing labor intensity and making for easier maintenance to the print heads. | 01-26-2012 |
20130269178 | PRINTHEAD MOUNTING AND ADJUSTING MECHANISM FOR INKJET PRINTER - An improved print head mounting and adjusting mechanism for inkjet printers. The mechanism include multi-bottom bracket, multi-top bracket and a base plate, the bottom bracket is used to provide accurate movement adjustment on the Y-axis direction, the top bracket is used to provide accurate rotation adjustment around the Z-axis direction, wherein also include a head mounting bracket for installing print head, then the head mounting bracket is mounted on the bottom bracket. The print head and the adjustment mechanism are two separate parts, so exchanging or adjusting it will not damage the print heads. Remounting a print head requires a slight adjustment to reach the desired position reducing labor intensity and making for easier maintenance to the print heads. | 10-17-2013 |
20130314469 | PRINTHEAD MOUNTING AND ADJUSTING MECHANISM FOR INKJET PRINTER - The mechanism include a bottom bracket and a base plate, the bottom bracket is mounted on the base plate to provide accurate Y-axis movement and adjustment, wherein also include a top bracket which is mounted on the bottom bracket for providing angle adjustment of the print head. Micrometer screw head is used as the adjustment mechanism for fine precision adjustment. The print head and the adjustment mechanism are two separate parts, so exchanging or adjusting it will not damage the print heads. Remounting a print head requires a slight adjustment to reach the desired position reducing labor intensity and making for easier maintenance to the print heads. | 11-28-2013 |
20130335465 | INKJET PRINTER'S INK PROTECTION METHOD - The present invention relates to a kind of inkjet printer's ink protection method including: the developer generates a rechargeable code in accordance with the print head's nPL, total ink volume G | 12-19-2013 |
20140285565 | INKJET PRINTING APPARATUS AND PRINTING METHOD - The present invention provides an inkjet printing apparatus, including a conveyer system to place and transmit print substrates, a printing module with at least one print head installed to eject ink droplets on the print substrates and the control system to control the movement of print head and conveyer system, wherein the conveyer system has an integrated design with no less than two stations to conduct different processing operations of the print substrates. By adopting the integrated design of multi-stations on the conveyer system, the structure of the inkjet printing apparatus in the present invention becomes more compact, its size becomes smaller and the costs are lowered. At the same time, the simultaneous and semi-automatic operation for loading, printing and collection is realized and thus inkjet printing efficiency enhanced. This integrated design of multi-stations also secures the safety of loading and collection by controlling the printing module to move in the range of the printing station. | 09-25-2014 |
20140292855 | INKJET PRINTING APPARATUS AND PRINTING METHOD - The present invention provides an inkjet printing apparatus that includes at least one print head jetting coating inks, several print heads jetting color inks and a control system controlling print heads, wherein the print heads jetting coating inks and those jetting color inks are in three rows with print heads jetting color inks in the first and third row and those jetting coating inks in the second row, and print heads jetting the same color ink are the same in number. The control system controls all print heads in the three rows to jet inks at the same time to realize double-image printing. The inkjet printing apparatus in the present invention can realize pre-coat printing, post-coat printing, double-image printing and double-speed printing by controlling different rows of print heads to eject ink droplets. In the double-image printing mode, the two images can be the same or different. If the two images are the same, transparency of one of the images can be adjusted. | 10-02-2014 |
Patent application number | Description | Published |
20090068211 | IMMUNOGENICALLY-ENHANCED POLYPEPTIDES AND RELATED METHODS - Described herein are immunogenically-enhanced polypeptides, such as KSHV LANA1 polypeptides, related methods of eliciting an immune response to the polypeptides and related nucleotide sequences. Also described herein are novel polypeptides capable of inhibiting degradation and/or retarding synthesis of a protein when attached to or incorporated within that protein along with related methods and nucleotide sequences. | 03-12-2009 |
20110135598 | METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA - The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases. | 06-09-2011 |
20120269854 | Method of Enhancing KSHV LANA1 Immunogenicity - An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein. | 10-25-2012 |
20140037581 | METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA - The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases. | 02-06-2014 |
20150086535 | Use of Survivin Antagonists in Polyomavirus-Related Disease - A method of treating a polyomavirus (+) cancer in which survivin is upregulated in a patient is provided, comprising administering to the patient a therapeutically effective amount of a composition that downregulates survivin expression or function in cells of the polyomavirus (+) cancer. A method of reducing growth of polyomavirus (+) cancer cells in which survivin is up-regulated is provided, comprising contacting the cells with an amount of a composition that downregulates survivin expression or function effective to reduce growth of the cells. Also provided is sepantronium salt, for use in treating a polyomavirus (+) cancer in which survivin is up-regulated. | 03-26-2015 |
20160046696 | METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA - The present invention provides murine monoclonal antibody molecules that bind to Merkel cell carcinoma (MCV) polypeptides. | 02-18-2016 |